Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
49 hedge funds and large institutions have $90.8M invested in Allena Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
7% more funds holding
Funds holding: 46 → 49 (+3)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
52% less capital invested
Capital invested by funds: $188M → $90.8M (-$97.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$650K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$431K |
| 3 |
FI
Fosun International
Hong Kong,
China
|
+$258K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$147K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$1.01M |
| 2 |
AA
ALPS Advisors
Denver,
Colorado
|
-$394K |
| 3 |
Morgan Stanley
New York
|
-$241K |
| 4 |
Goldman Sachs
New York
|
-$238K |
| 5 |
NIM
Needham Investment Management
New York
|
-$200K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Goldman Sachs
New York
| – | -$238K | -22,177 | Closed |
|
52
Two Sigma Investments
New York
| – | -$162K | -15,080 | Closed |
|
53
Barclays
London,
United Kingdom
| – | -$49K | -4,629 | Closed |
|
|
NIM
54
Needham Investment Management
New York
| – | -$200K | -4,616 | Closed |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3K | -237 | Closed |
|
ALNA Hedge Fund Activity: Q4 2018 in Review
49 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q4 2018, worth a combined $90.8M — down 52% from $188M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ALNA positions and 6 closed out — a net gain of 4 holders — while 12 added to existing stakes and 12 trimmed.
The largest buyer was Vanguard Group, adding an estimated $650K. The largest seller was Perceptive Advisors, cutting an estimated $1.01M.
- 49 institutional investors held Allena Pharmaceuticals (ALNA) as of Q4 2018, up from 46 in Q3 2018.
- Funds reported $90.8M of Allena Pharmaceuticals stock for Q4 2018, down 52% quarter-over-quarter.
- 10 funds opened new Allena Pharmaceuticals positions in Q4 2018 and 6 closed out, a net change of +4 holders.
- The largest Allena Pharmaceuticals buyer in Q4 2018 was Vanguard Group, an estimated $650K added.
- The largest Allena Pharmaceuticals seller in Q4 2018 was Perceptive Advisors, an estimated $1.01M sold.
Based on aggregated 13F filings for Q4 2018.